StreetInsider.com News Articles

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Tue, 02 Jun 2026 07:03:00 -0400

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026.

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Tue, 02 Jun 2026 07:03:00 -0400

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39

Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord

Wed, 27 May 2026 06:55:19 -0400

(Updated - May 27, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $11.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "Last week we hosted a virtual NDR with OCGN management including Co-founder, Chairman and CEO Shankar Musunuri, Ph.D, MBA; CFO Rita Johnson-Greene, MBA; and CSO & Head of R&D Arun Upadhyay, Ph.D. Discussion focused on the upcoming blinded interim from the Ph2/3 study of OCU410ST in Stargardt disease, recent Ph2 data from OCU410 in geographic atrophy, and next trial design and BLA prep ahead of 1Q27 Ph3 data for

Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord

Wed, 27 May 2026 06:55:19 -0400

(Updated - May 27, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $11.00 (from $12.00) while maintaining a Buy rating.

Ocugen appoints new acting chief medical officer

Thu, 14 May 2026 16:41:47 -0400

Ocugen Inc. (NASDAQ: OCGN) announced leadership changes in its medical department. Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer effective May 8, 2026.

The company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer on the same date, according to the company's filing.

Ocugen appoints new acting chief medical officer

Thu, 14 May 2026 16:41:47 -0400

Ocugen Inc. (NASDAQ: OCGN) announced leadership changes in its medical department. Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer effective May 8, 2026.

The company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer on the same date, according to the company's filing.

Form 8-K Ocugen, Inc. For: May 08

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495776.html

Form 8-K Ocugen, Inc. For: May 08

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495776.html

Form 8-K Ocugen, Inc. For: May 14

Thu, 14 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260514/26495705.html

Form 8-K Ocugen, Inc. For: May 14

Thu, 14 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260514/26495705.html

Ocugen raises $130 million through convertible notes offering

Thu, 14 May 2026 16:30:15 -0400

Ocugen Inc. (NASDAQ: OCGN) completed a private offering of $130 million in 6.75% convertible senior notes due 2034, the biotechnology company announced. The offering included the full exercise of a $15 million over-allotment option by the initial purchaser.

The notes were sold at 90% of their principal amount to qualified institutional buyers under Rule 144A of the Securities Act of 1933. After deducting the initial purchaser's discount and estimated offering expenses, Ocugen expects to receive approximately $112.6 million in net proceeds.

The company used approximately $32.7 million of the proceeds to fully repay outstanding principal and accrued interest on a loan with

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Thu, 14 May 2026 16:30:00 -0400

Includes Full Exercise of $15.0 million Over-Allotment Option

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), including the full exercise by the initial purchaser of its option to purchase an additional $15.0 million aggregate principal amount of

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Thu, 14 May 2026 16:30:00 -0400

Includes Full Exercise of $15.0 million Over-Allotment Option

Ocugen to Participate in Upcoming May Scientific and Investor Conferences